Sialic acids are widespread in biology, fulfilling a wide range of functions. Their cognate lectin receptors -Siglecs -are equally diverse and widely distributed, with different Siglecs found within distinct populations of cells in the haemopoietic, immune and nervous systems. A convenient way to assay ligand recognition of soluble Siglecs would be useful, as would methods for the concomitant assessment of Siglec distribution on cell surfaces. Here we report the use of gold nanoparticles functionalised with a sialic acid ligand diluted with a polyethylene glycol (PEG) ligand for the plasmonic detection of a soluble form of murine Siglec-E (mSiglec-E-Fc fusion protein) and, importantly, for the specific detection of the same siglec expressed on the surface of mammalian cells. These sialic acid functionalised nanoparticles are shown to overcome problems such as cellular cis interactions and low Siglec-ligand affinity. The gold nanoparticles were functionalised with various ratios of sialic acid:PEG ligands and the optimum ratio for the detection of murine Siglec-E was established based on the plasmonic detection of the soluble pre-complexed recombinant form of murine Siglec-E (mSiglec-E-Fc fusion protein). The optimum ratio for the detection of the fusion protein was found to be sialic acid:PEG ligands in a 50:50 ratio (glyconanoparticles 1).
Introduction
Siglecs are a family of sialic acid-binding immunoglobulin-like lectins that are found on many immune system cell types where they regulate the functions and interactions of such cells. [1] [2] [3] [4] Siglecs are type-I cell surface transmembrane receptors that are formed by 2-17 extracellular immunoglobulin-like domains, 4 including varying numbers of C2-set domains (from 16 in Siglec-1 to 1 in Siglec-3) and an amino-terminal V-set that contains a conserved arginine residue that mediates the carbohydrate binding activity. 5 Human Siglecs (hSiglecs) and murine Siglecs (mSiglecs) can be divided into two sub-groups based on sequence similarity and evolutionary conservation. 6 The first group consists of sialoadhesin (Siglec-1), CD22 (Siglec-2), myelin-associated glycoprotein (Siglec-4) and Siglec-15. The second subgroup, known as the CD33-related Siglecs, consists of CD33 (Siglec-3) plus Siglecs-5-11 and 14 in humans and Siglec-E-H in mice; which are found mainly on mature cells of the immune system, such as natural killer (NK) cells, mast cells, neutrophils, eosinophils and macrophages. CD33-related Siglecs are involved in the inhibition of proliferation and in the induction of apoptosis, 7, 8 inhibit the killing function of NK cells against tumours expressing sialylated glycans, 9 and are highly expressed in acute myeloid leukaemia and human blood leukocytes. 10, 11 In mouse, neutrophils and tissues rich in leukocytes express high levels of mSiglec-E. mSiglec-E is structurally similar to both hSiglec-7 and -9, with all three siglecs containing an amino-termina V-set and two C2-set immunoglobulin domains in the extracellular membrane and an immunoreceptor tyrosine-based inhibitory (ITIM) motif and an ITIM-like domain in the cytoplasmic tail (Fig. S1 ). 3 Thus, mSiglec-E is expressed in most of the cell types that express either hSiglec-7 or hSiglec-9. 12 However, although these human and mice Siglecs are structurally similar, they differ in some of the amino acid residues present in each of the structural components 13 (the sequence similarity between hSiglec-7 and -9 and mSiglec-E is 52% and 53%, respectively). 14 The peptide variability between these three Siglecs is responsible for their differences in sialic acid binding specificities. 13 To date, there is insufficient information to fully understand the biological roles that hSiglecs play in vivo. The development of murine-based animal models and the study of the structurally equivalent hSiglecs in mice have provided some insights. 15 4 CD33-related Siglecs have been exploited as targets for different treatment strategies. 16 For example, CD33 and CD22 are markers of myeloid leukemia and B-cell malignancies and have been used as targets of antibody-drug conjugate-based treatments. 17 An immunoconjugate of anti-CD33-antibody with the antibiotic calicheamicin was commercialised for the treatment of acute myeloid leukaemia (Mylotarg®). 18 hSiglec-7, overexpressed on a variety of cancer cells, 19 has been used as a target for the drug delivery of antibody-functionalised poly(lactide-co-glycolide) nanoparticles. 20 Recently, the use of liposomal nanoparticles functionalised with glycan ligands that bind specifically to a Siglec of interest such as hCD33 and hCD22, 21 sialoadhesin/Siglec-1, 22 Siglec-9 23 and Siglec-7 24 has been extensively reported by Paulson and co-workers. These studies use fluorescence-based techniques to elucidate the behaviour of the nanoparticles within the cells. However, such techniques do not allow single particle detection and cannot provide information regarding localisation at the structural level that could be achieved with electron microscopy. Recently, artificial viruslike glycosphingolipid-functionalised nanoparticles incorporating 80 nm gold nanoparticles were used, in combination with scanning electron microscopy, to understand the behaviour of human immunodeficiency virus-1 when bound to Siglec-1 receptors expressed on HeLa cells. 25 Gold nanoparticles (AuNPs) allow for the use of electron microscopy techniques to obtain high resolution images, and are ideal for the development of plasmonic bioassays since the colour of a solution of nanoparticles depends on the localised surface plasmon fields which are, in turn, dependent on the distance between particles. 26 AuNPs have been functionalised with carbohydrate derivatives (glyconanoparticles) and used for the plasmonic detection of analytes of biological interest. 27 AuNPs (ca. 15 nm) exhibit a surface plasmon absorption band centred at 520 nm and, consequently, are red in colour. When the particles aggregate due to the presence of the target analyte, the surface plasmon absorption band red-shifts producing a colour change in the solution. With this change of colour, glyconanoparticles have been used for the detection of biological targets such as concanavalin A (ConA), 28, 29 cholera toxin 30 and Ricinus communis Agglutinin 120 (RCA120). 31 Sialic acid functionalised gold nanoparticles have been used for the inhibition and detection of influenza virus 32, 33 and more recently for the detection and discrimination between human and avian influenza viruses. 34 Silver nanoparticles functionalised with both sialic acid 5 and galactose derivatives have been used in combination with extinction and surface enhanced Raman (SER) spectroscopies for the detection of cholera toxin. 35 A further advantage that the glyconanoparticles possess for the detection of Siglecs expressed on the surface of cells is their potential to overcome problems that other detection methods encounter including the presence of cis interactions and the low Siglecligand affinity. When interactions between Siglec and sialic acid are described, the initial assumption is that the Siglec of one cell binds glycans terminating in sialic acid that are on a second cell (in trans) and therefore, an intercellular adhesion takes place. [36] [37] [38] However, since the concentration of sialic acid terminated glycans on the surface of a cell is high, Siglecs can also bind those sialic acids of glycans expressed on the same cell (in cis). [36] [37] [38] The binding sites of the Siglecs are then 'masked' by the sialic acid in cis, which can be reduced if an external ligand with higher affinity towards the Siglec is present. However, Siglec-ligand interactions are usually weak. These problems can be overcome using multivalent ligandbased probes 36 such as glyconanoparticles where a large number of carbohydrate-based ligands can be attached onto the surface of AuNPs.
In this paper we describe, to the best of our knowledge, the first glyconanoparticles that enable the plasmonic detection of Siglecs in solution and, importantly, using the same glyconanoparticle based platform for the detection of Siglecs expressed on the surface of transfected Chinese hamster ovary (CHO) cells using transmission electron microscopy (TEM). AuNPs (ca. 15 nm) were functionalised with a S-linked sialic acid derivative ligand (sialic acid ligand 1) and a thiolated polyethylene glycol derivative ligand (PEG ligand 2) yielding glyconanoparticles (Fig. 1) . Different ratios of the sialic acid ligand 1 and PEG ligand 2 were studied and the optimum ratio was determined following the plasmonic detection of mSiglec-E-Fc cross-linked with an anti-Fc-IgG-antibody (mSiglec-E-Fc/antibody-complex) in solution (Fig. 2a) . The optimum ratio for the plasmonic detection of the pre-complexed mSiglec-E-Fc was found to be 50:50 (glyconanoparticles 1). This solution based plasmonic assay enabled the study of selectivity and specificity of the designed platforms in an easy and rapid manner. The optimised glyconanoparticles 1 were subsequently used for the detection of mSiglec-E expressed on the surface of transfected CHO cells. The sialic acid 6 ligand on the glyconanoparticles recognised and interacted with the mSiglec-E expressed on the cell surface (Fig. 2b ) which was then visualised using TEM. 
Experimental
Synthesis of the sialic acid ligand 1 Sialic acid ligand 1 was synthesised using a previously reported protocol 34 as detailed in 
Synthesis of N-Boc-2,2'-(ethylenedioxy)bis(ethylamine) (3)
Compound 3 was synthesised from the corresponding diamine following a published procedure. 39 
Synthesis of t-butyl 2-(2-(2-(2-iodoacetamido)ethoxy)ethoxy)ethylcarbamate (4)
Iodoacetic anhydride (555 mg, 1.57 mmol) was dissolved in absolute diethylether (Et2O, 10 mL) and the solution was added to a stirred solution of compound 3 (299.6 mg,
1.21 mmol) in absolute diethylether (10 mL) under N2 and with the exclusion of light. The mixture was allowed to stir for 60 min at r.t. and the formation of product was followed by 9 TLC (Rf=0.67, ethyl acetate/methanol 20:1). The volatiles were evaporated in vacuo and the residue was subjected to column chromatography on silica gel (using first ethyl acetate followed by ethyl acetate/methanol 20:1) to give pure 4 (353.5 mg, 70%) as a pale yellow oil. The characterisation of compound 4 is given in the Electronic Supplementary Information.
Synthesis of N-(2-(2-(2-(2-hydroxyacetamido)ethoxy)ethoxy)ethyl)-4-mercaptobutanamide (2)
4 (50 mg, 120 μmol) and K2CO3 (83 mg, 600 μmol) were heated to 80 o C in a mixture of dimethylformamide (DMF, 0.5 mL) and water (0.5 mL). After 6 h, when TLC showed complete conversion (hydroxyacetamide 7; Rf=0.42, chloroform/methanol 10:1), the volatiles were evaporated in vacuo. Acetic acid (50%, 234 μL) was added and the volatiles were evaporated in vacuo.
hydroxyacetamido)ethoxy)ethoxy)ethylcarbamate (7) was dissolved in dichloromethane (DCM, 1 mL) and trifluoroacetic acid (TFA, 1 mL) was added. The mixture was stirred at r.t. 
Synthesis of gold nanoparticles and functionalisation with sialic acid ligand 1 and PEG ligand 2 -glyconanoparticles
Water soluble citrate-reduced gold nanoparticles were prepared via the citrate reduction of hydrogen tetrachloroaurate (HAuCl4) following the method reported by Enüstün and Turkevich. 40 Briefly, aqueous solutions of HAuCl4·3H2O (12.5 mg, 32 μmol, in 100 mL) and 
Cross-linking of mSiglec-E and hSiglec-7 with goat anti-human (Fc specific) antibody (mSiglec-E-Fc/antibody-complex and hSiglec-7-Fc/antibody-complex, respectively)
The Fc fusion proteins mSiglec-E and hSiglec-7 were cross-linked with an anti-Fc antibody, goat anti-human-Fc-IgG antibody, prior to use following a previously reported protocol. 41 Briefly, a 50 µL mixture of the Fc fusion protein (2 mg/mL) and goat anti-human-Fc-IgG antibody (2 mg/mL) was incubated for 1 h at room temperature. The resulting complex was diluted in phosphate buffer saline (1.6 mL) prior to use. The complexes obtained were denoted as: mSiglec-E-Fc/antibody-complex for the mSiglec-E-Fc cross-linked with the antibody and hSiglec-7-Fc/antibody-complex for the hSiglec-7-Fc cross-linked with the antibody.
Plasmonic detection of mSiglec-E-Fc/antibody-complex using the varying ratio sialic acid ligand 1:PEG ligand 2 functionalised gold nanoparticles
Increasing amounts of mSiglec-E-Fc/antibody-complex (from 0 to 4.7 μg) were added to a sample of the sialic acid ligand 1:PEG ligand 2 functionalised AuNPs of varying ratios (concentration of nanoparticles = ca. 2 nM). The UV-Vis extinction spectrum of each glyconanoparticle solution was measured before and after addition of the corresponding amount of mSiglec-E-Fc/antibody-complex.
Control experiments

Plasmonic detection of anti-Fc antibody
Glyconanoparticles 1 (ca. 2 nM) were reacted with goat anti-human-Fc-IgG antibody (from 0 to 6.25 µg). The UV-Vis extinction spectrum of the solution was measured before and after addition of increasing amounts of antibody.
Plasmonic detection of mSiglec-E using gold nanoparticles functionalised only with PEG ligand 2
mSiglec-E-Fc/antibody-complex (2.35 µg) was added to a sample of PEG ligand 2 functionalised gold nanoparticles (ca. 2 nM). The UV-Vis extinction spectrum of the solution was measured before and after addition of the mSiglec-E-Fc/antibody-complex.
Plasmonic detection of hSiglec-7-Fc/antibody-complex
hSiglec-7-Fc/antibody-complex (2.35 µg) was added to a sample of glyconanoparticles 1 (ca.
2 nM). The UV-Vis extinction spectrum of the solution was measured before and after addition of the hSiglec-7-Fc/antibody-complex.
Cellular experiments using CHO cells expressing mSiglec-E and wild-type CHO
CHO cells were transfected to express mSiglec-E as described previously. 42 Both wild-type CHO cells and CHO cells expressing mSiglec-E were cultured in HAMS F12 medium supplemented with 10% foetal calf serum, penicillin (100 U/mL) and streptomycin (100 µg/mL).
To perform the cellular experiments, glyconanoparticles 1 (ca. 2 nM) were mixed with 10 6 cells, either CHO cells expressing mSiglec-E or with wild-type CHO cells, for 10 min at r.t.
Transmission electron microscopy imaging
TEM imaging of glyconanoparticles in the absence and presence of mSiglec-E-Fc/antibodycomplex
A sample of the glyconanoparticles (ca. 10 μL), before and after being reacted with mSiglec-E-Fc/antibody-complex (2.35 μg) for 2 h, was deposited on a holey carbon film 300 mesh copper grids from Agar Scientific (UK) and imaged using a Jeol 200EX transmission electron microscope. 
TEM imaging of cells
Synthesis of the glyconanoparticles
The synthesis of water soluble AuNPs (ca. 15 nm) was achieved using citrate as both the reducing agent and the stabiliser of the gold core. 40 The suspension of the citrate AuNPs was red in colour as a consequence of the surface plasmon absorption band centred at ca. 
Plasmonic detection of Siglecs in solution using the glyconanoparticles
Siglecs are naturally expressed on the surface of cells where they can occur in clusters via lateral diffusion. 3 To mimic the cell surface configuration of these proteins, a multivalent presentation of the Siglecs is required. Surface plasmon resonance analysis has previously shown that, without cross-linking with an antibody, monomeric hSiglec-7-Fc exhibits only a weak binding to sialic acid derivatives. 41 Multivalent formats for the study of selective recognition by Siglecs have been also achieved following pre-complexation of mSiglecs-Fc and hSiglecs-Fc with the corresponding antibodies. [45] [46] [47] The need of the formation of a precomplex Siglec-Fc-antibody to observe binding between Siglecs and recognition ligands was also reported, despite the bivalency of the tested Siglec-Fc, when polyacrylamide probe 14 beads with pendant carbohydrate ligands were used for the recognition of Siglecs. 36 In the research presented here, the multivalent presentation of the Siglecs was achieved by crosslinking the different dimeric Siglec-Fc chimaeric proteins with an anti-Fc-IgG antibody. When the mSiglec-E-Fc/antibody-complex is added to a solution of glyconanoparticles, the mSiglec-E in the antibody-complex will recognise the sialic acid on the nanoparticles surface and will bind to it. mSiglec-E has been reported to bind strongly to α2,6-and α2,3-linked sialic acids (Fig. S3) ; 3, 4, 12 thus, it is anticipated that mSiglec-E should recognise the sialic acid ligand 1 present on the designed glyconanoparticles. The binding of the mSiglec-E to the sialic acid will induce the aggregation of the glyconanoparticles (Fig. 2a) and a colour change in the solution should be observed by eye and also by recording the UV-Vis extinction spectrum of the solution before and after addition of the mSiglec-E-Fc/antibody-complex.
The effect of the carbohydrate density on the surface of the AuNPs upon the efficacy of the binding to targets of interest has been highlighted previously. 31, 34 To achieve the optimal plasmonic detection of mSiglec-E, AuNPs were functionalised with different ratios of sialic used. 48 Consequently, to control the ratio of the ligands on the surface of the nanoparticles and following the work reported previously by Barrientos et al., 49 we selected PEG ligand 2 as the dilutant since it is structurally equivalent to the aliphatic side chain of the sialic acid ligand 1. Thus, the sialic acid ligand 1:PEG ligand 2 ratio functionalising the surface of the nanoparticles was expected to be in the same ratio as the molar ratio added to the solution of citrate-reduced AuNPs. To obtain the optimal ligand density on the glyconanoparticles for the plasmonic detection of mSiglec-E, increasing amounts of mSiglec-E-Fc/antibody-complex (from 0 to 4.7 µg) were added to the corresponding glyconanoparticles solution and the UVVis extinction spectrum of each sample was measured before and after addition of the mSiglec-E-Fc/antibody-complex (Fig. 3) . The addition of mSiglec-E-Fc/antibody-complex to AuNPs functionalised with sialic acid ligand 1:PEG ligand 2 (100:0) induced only a slight shift in the surface plasmon absorption band (Fig. 3a) , suggesting that a full monolayer of sialic acid derivative was not a suitable coverage to induce aggregation of the particles in the presence of the mSiglec-E-Fc/antibody-complex. Reducing the sialic acid coverage, AuNPs functionalised with sialic acid ligand 1:PEG ligand 2 (50:50), proved to be a more sensitive assay for the plasmonic detection of mSiglec-E (Fig. 3b) . While high concentrations of the Siglec were still required to induce aggregation, there was a greater shift in the surface plasmon absorption band (indicated with a horizontal arrow in Fig. 3b ) as compared to the shift observed in Fig. 3a for a full Upon addition of mSiglec-E-Fc/antibody-complex (4.7 µg), the greatest change in the extinction intensity at 620 nm was 0.065 units; while the greatest shift in the wavelength extinction maximum was 3 nm. Both changes were observed for the AuNPs functionalised with sialic acid ligand 1:PEG ligand 2 (50:50) (Fig. 3b) . These results suggest that the 50:50 ratio of sialic acid ligand 1:PEG ligand 2 on the AuNPs, glyconanoparticles 1, exhibit the greatest interaction with the mSiglec-E inducing the largest aggregation of the glyconanoparticles upon addition of the Fc-fusion protein.
TEM was used to further confirm the aggregation of the glyconanoparticles 1 in the presence of the mSiglec-E-Fc/antibody-complex. TEM images of the glyconanoparticles 1 before addition of mSiglec-E-Fc/antibody-complex showed dispersed nanoparticles ( Fig. 4a and S4a). When the glyconanoparticles 1 were mixed with mSiglec-E-Fc/antibody-complex (2.35 µg) for 2 h, networks of particles were observed in the TEM images of the sample, confirming the aggregation of the particles (Fig. 4b and S4b) . The aggregation of the particles was also observed by the naked eye with a colour change from red to light pink that was visible 10 min following addition of the mSiglec-E-Fc/antibody-complex (Fig. 4c) . Two control experiments were performed to confirm that the aggregation of the glyconanoparticles 1 in the presence of mSiglec-E-Fc/antibody-complex was specifically due to the binding of the mSiglec-E to the sialic acids on the glyconanoparticle surface.
Increasing amounts of goat anti-human-Fc-antibody (from 0 to 6.25 µg) were added to a solution of glyconanoparticles 1 and the UV-Vis extinction spectrum was recorded following each addition. Changes of the surface plasmon absorption band of the glyconanoparticles 1 upon addition of the control antibody were negligible (Fig. 5a) . Thus, the changes observed in the surface plasmon absorption band of the glyconanoparticles in the presence of the mSiglec-E-Fc/antibody-complex (Fig. 3b) were due to the mSiglec-E. To confirm the importance of the sialic acid for the specific detection of mSiglec-E, AuNPs functionalised with the PEG ligand 2 alone were synthesised and the UV-Vis extinction spectrum of the sample was measured before and after addition of increasing amounts of mSiglec-EFc/antibody-complex (Fig. 5b) . No changes in the extinction spectrum were observed following addition of the mSiglec-E-Fc/antibody-complex, which further highlights the importance of the sialic acid derivative for the detection of mSiglec-E using the A further control experiment was performed to investigate the binding affinity of glyconanoparticles 1 towards hSiglec-7. hSiglec-7 expresses a unique preference for α2,8-linked disialic acid over α2,6-linked and α2,3-linked sialic acids (Fig. S3) . 3, 4, 12, 50 While both hSiglec-7 and hSiglec-9 are structurally similar to mSiglec-E, the binding specificity of hSiglec-7 is more similar to that of mSiglec-E (Fig. S3) . Thus, it was considered that hSiglec-7
would be a suitable control to study the specificity of binding of the glyconanoparticles 1.
No change of the surface plasmon absorption band of glyconanoparticles 1 was observed upon addition of the hSiglec-7-Fc/antibody-complex (2.35 µg) (Fig. S5) . Further, the changes of the surface plasmon absorption band of the glyconanoparticles upon addition of the hSiglec-7-Fc/antibody-complex were compared with those observed upon addition of the same amount of the mSiglec-E-Fc/antibody-complex ( To ensure that the glyconanoparticles are specifically binding to the mSiglec-E receptors on the cell surface, wild-type CHO cells not expressing mSiglec-E on their surface were added to the glyconanoparticles 1 and the sample imaged using TEM (Fig. S8) . The TEM images show that there are no nanoparticles bound to the surface of the cells confirming that the glyconanoparticles specifically bind to the CHO cells expressing mSiglec-E via sialic acidSiglec interactions. In a final control experiment, mSiglec-E CHO cells without nanoparticles were imaged following staining of the sample (Fig. S9) . As expected, no nanoparticles were observed in the TEM images of the control sample.
Conclusions
The primary aim of this research was to detect the sialic acid-binding immunoglobulin-like The developed method can be used in the future to assess the distribution of Siglecs expressed on the surface of different cell types and can consequently, contribute to further our understanding of the biological roles that these lectins play in vivo.
